Abstract
The National Institute of Neurological Disorders and Stroke (NINDS) trialwas groundbreaking.1It demonstrated that stroke patients could be admitted to hospital, scanned,and treated within 3 hours of stroke, a major achievement in the early 1990s.The Food and Drug Administration accepted the NINDS evidence (actuallyconducted as 2 consecutive trials, only 1 of which gave positive results) andlicensed recombinant tissue plasminogen activator (tPA) for the treatment ofstroke.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
